New drug combo could spare bladder cancer patients from surgery

NCT ID NCT03504163

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether combining two immune-boosting drugs, pembrolizumab and BCG, can keep high-risk bladder cancer from coming back. About 45 people with early-stage but aggressive bladder cancer will receive this combination as their first treatment. The goal is to see if most patients remain cancer-free at 6 months, potentially avoiding the need to remove the bladder.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma superficial urinary bladder carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, 10065, United States
Memorial Sloan Kettering Bergen (All protocol activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering West Harrison (All Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.